Table 1 Comparison of general data between the two groups.
Variables | Experimental group (SCS) | Control group (PRF) | Statistical value | P-value | |
|---|---|---|---|---|---|
Gender | Male | 58(45.67%) | 71(47.97%) | 0.068 | 0.795 |
Female | 69(54.33%) | 77(52.03%) | |||
Age | 68.57 ± 8.99 | 65.91 ± 11.84 | –2.12 | 0.035 | |
Disease duration | Acute Phase | 32(25.20%) | 67(45.27%) | 13.13 | 0.001 |
Subacute Phase | 57(44.88%) | 55(37.16%) | |||
Sequelae Phase | 38(29.92%) | 26(17.57%) | |||
Side | Left | 65(51.18%) | 68(45.95%) | 0.75 | 0.386 |
Right | 62(48.81%) | 80(54.05%) | |||
VAS score | 6.78 ± 0.77 | 6.62 ± 0.74 | 0.091 | 0.083 | |
PQSI | 15.79 ± 1.48 | 15.73 ± 1.39 | 0.17 | 0.739 | |
BPI | 34.61 ± 3.04 | 34.14 ± 3.44 | 0.39 | 0.232 | |
HADS-A Score | 12.27 ± 0.18 | 12.11 ± 0.16 | 0.24 | 0.488 | |
HADS-D Score | 12.87 ± 1.72 | 12.71 ± 1.50 | 0.19 | 0.420 | |
Complication | Yes | 1(0.79%) | 1(0.68%) | 0.012 | 0.913 |
No | 126(99.21%) | 147(99.32%) |